Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

Neurology

Volumn 73, Issue 15, 2009, Pages 1200-1206

  Iwamoto, F M ^a,b,c   Abrey, L E ^a,b   Beal, K ^a,b   Gutin, P H ^a,b   Rosenblum, M K ^a,b   Reuter, V E ^a   Deangelis, L M ^a,b   Lassman, Andrew B ^a,b  

^a Department of Neurology ^*

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; ENZASTAURIN; ERLOTINIB; GIMATECAN; IRINOTECAN; PERIFOSINE; RAPAMYCIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; MALE; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RELAPSE; SALVAGE THERAPY; TREATMENT FAILURE; TUMOR GROWTH;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 70350142397     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bc0184     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for gli-oblastoma. N Engl J Med 2005;352:987-996.
2. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
3. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10: 162-170.
4. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fill-brandt R, Westphal M. Levels of soluble vascular endothe-lial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 2003;9:1399-1405.
5. Plate KH, Breier G, Weich HA, Risau W. Vascular endothe-lial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
7. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinote-can at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
8. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
9. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bev-acizumab plus irinotecan in recurrent glioblastoma multi-forme. J Clin Oncol 2007;25:4722-4729.
10. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008;88:339-347.
11. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
12. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol Epub 2009 Mar 30.
13. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
14. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-163.
15. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992;24:55-57.
16. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-911.
17. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628.
18. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-314.
19. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220.
20. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
21. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevaci-zumab and chemotherapy. Neurology 2006;66:1258-1260.
22. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008;5:634-644.
23. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
24. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
25. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
26. Haapasalo JA, Nordfors KM, Hilvo M, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 2006;12:473-477.
27. Korkolopoulou P, Perdiki M, Thymara I, et al. Expression of hypoxia-related tissue factors in astrocytic gliomas: a multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 2007;38:629-638.
28. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor an-giogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-278.
29. Fischer I, Cunliffe CH, Bollo RJ, et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008;10:700-708.
30. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-1222.
31. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-2621.